Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The user is experiencing hair loss and is using treatments like finasteride, minoxidil, and hormone replacement therapy (estradiol enanthate injections) to address it. They are advised to be patient with the treatments and consider using a dermapen for microneedling.

The user has been using finasteride 1mg and oral minoxidil 2.5mg for a year, experiencing ongoing shedding since starting minoxidil. They are considering dutasteride and seeking advice on blood work for thyroid, Vitamin D, and iron levels.

Hmi115, a prolactin receptor blocker, showed promise for hair growth, but results from Phase 2 trials have not been published. ABS-201, an AI-based analog, is expected to begin trials in December 2025, while commercialization of treatments like PP-405 is anticipated around 2027.

The conversation discusses potential hair loss treatments focusing on stimulating IGF-1 at the follicle level using growth-factor cocktails and engineered peptides, such as Acetyl Tetrapeptide-3, Copper Tripeptide-1, Oligopeptide-20, Thymosin-β4, and Palmitoyl Tetrapeptide-7. It suggests that device-assisted delivery methods like microneedling may enhance effectiveness.

Using DIM and Calcium D-Glucarate to reduce finasteride side effects. Discussion includes dosage, brand, and product effectiveness.

The user has been using oral finasteride for over a year and recently added GHK-CU for two months, seeing progress but seeking further improvement, especially on the hairline. They discuss sourcing GHK-CU, its effects, and the importance of third-party testing, while considering additional treatments like dutasteride and hair transplants for better results.

The conversation discusses a topical finasteride therapy with hydrocortisone butyrate, estrone base, and breviline. A user suggests oral finasteride as a superior option.

A 21-year-old male with advanced hair loss (NW7) started using finasteride and minoxidil 10 months ago but hasn't seen much progress. He is pre-diabetic with stage 1 hypertension and is seeking insights on whether treating these conditions could improve hair regrowth.

A user experiencing hair loss since age 18 is considering switching from finasteride and minoxidil to dutasteride after poor results and lifestyle choices. They plan to improve their lifestyle and get blood work done to assess treatment effectiveness.

The user reported positive results in hair density and skin improvement using a combination of oral Minoxidil, Finasteride, and subcutaneous GHK-Cu. They experienced less shedding with oral Minoxidil compared to topical and noted significant skin benefits from GHK-Cu.

Dutasteride and finasteride are used for hair loss, affecting hormone levels like DHT and testosterone. Hormone balance is crucial, as changes can lead to side effects such as increased estradiol and potential hair loss.

A 24-year-old male using topical finasteride for hair loss is experiencing thinning despite treatment and has high estrogen levels. He is seeking advice on whether high estrogen could be causing hair loss and how others with high estrogen levels have addressed it.

The user is taking 0.5mg finasteride and 0.5mg Loniten orally daily, using Eucapil twice weekly, and Minoxidil foam once daily for hair loss. They believe Eucapil effectively stops hair loss despite side effects like breast growth.

The user has been using finasteride and oral minoxidil for two years without improvement in diffuse thinning and is considering switching to dutasteride and getting a scalp biopsy. Suggestions include treating subclinical hypothyroidism, trying PRP therapy, and checking for autoimmune issues.

A 37-year-old woman with androgenetic alopecia is using spironolactone, oral and topical minoxidil, and considering PRP therapy due to lack of progress. She is unable to obtain finasteride, dutasteride, or bicalutamide and is exploring other options like Clascoterone and RU58841.

The user is experiencing reduced hair shedding and increased hair density after using finasteride, minoxidil, derma rolling, granactive retinoid, and Nizoral, while also taking testosterone and aromatase inhibitors. They question if they are a hyper responder to the treatments, despite mixed feedback from others about visible progress.

The user completed a Clascoterone study with no observable changes in hair loss and plans to try microneedling and Minoxidil next. They will microneedle weekly and apply Minoxidil twice daily, except on the night of microneedling, and compare results after six months.

The user added dutasteride once a week for three months and shared blood work results, noting low vitamin D. Another user mentioned experiencing hair thinning while on the same treatment.

Finasteride increased the user's estrogen levels by 51%, causing concerns about gynecomastia and sleep issues. Despite potential side effects, the user prefers continuing finasteride to prevent hair loss, considering it essential for self-esteem.

The user is considering blood tests to understand their receding hairline and is exploring brewer's yeast for its biotin content. They have been using topical Minoxidil, biotin, collagen, and microneedling, but are avoiding oral Finasteride and Dutasteride.

Clascoterone is promising for hair loss, showing 24.5% improvement in satisfaction compared to placebo. Users consider it an alternative to finasteride, with concerns about absorption and side effects.

A user shared their hair regrowth progress using Dutasteride, topical Minoxidil, Spironolactone, and Estradiol Valerate injections as part of hormone replacement therapy for transitioning. They experienced significant hair improvement and personal satisfaction but caution against this approach for non-transitioning individuals due to irreversible changes.

The conversation discusses personal experiences with hair loss and highlights the potential impact of anemia and nutrient deficiencies on hair health. Treatments mentioned include changing shampoo/conditioner, taking MSM, collagen, hyaluronic acid, astaxanthin, B12, folate, and bovine blood capsules.

PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.

Hope Medicine's HMI-115 is expected to be released in 2027, with phase 3 trials currently recruiting. Concerns include the safety of targeting prolactin and the potential cost of the treatment.

The user experienced significant hair regrowth and fullness after starting hormone replacement therapy (HRT) with sublingual estrogen and spironolactone, in addition to using a topical solution of minoxidil, finasteride, ketoconazole, and biotin. They noted initial shedding phases but emphasized that shedding is a sign of future growth.

A 26-year-old male with high testosterone is experiencing diffuse hair thinning despite using a comprehensive treatment regimen including dutasteride, oral minoxidil, RU58841, ketoconazole shampoo, microneedling, and low-level laser therapy. Suggestions include adjusting dutasteride dosage, monitoring iron levels, and consulting a dermatologist for further evaluation.

A user experienced increased estrogen levels after 11 months on finasteride, leading to concerns about feminizing effects. They plan to reduce the finasteride dosage and consider using an aromatase inhibitor to manage estrogen levels.

The clinic diagnosed the user with NW3 and AGA, noting thinning hair despite using finasteride for 3 years, and suggested PRP and Mesotherapy before considering a transplant. The user questions the necessity of these treatments without confirming retrograde alopecia and its treatability.

The user has been using a topical treatment combining finasteride, minoxidil, and caffeine for 9 months without noticing any changes and is inquiring about blood tests to check for finasteride resistance. They had their DHT levels checked, which were 54 ng/dl, and are planning to share progress pictures soon.